GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (STU:X0M1) » Definitions » Cyclically Adjusted Price-to-FCF

XOMA Royalty (STU:X0M1) Cyclically Adjusted Price-to-FCF : (As of Dec. 11, 2024)


View and export this data going back to 1986. Start your Free Trial

What is XOMA Royalty Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


XOMA Royalty Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for XOMA Royalty's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Royalty Cyclically Adjusted Price-to-FCF Chart

XOMA Royalty Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

XOMA Royalty Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of XOMA Royalty's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, XOMA Royalty's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XOMA Royalty's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA Royalty's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where XOMA Royalty's Cyclically Adjusted Price-to-FCF falls into.



XOMA Royalty Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

XOMA Royalty's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, XOMA Royalty's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.664/133.0289*133.0289
=-0.664

Current CPI (Sep. 2024) = 133.0289.

XOMA Royalty Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 -2.428 99.070 -3.260
201503 -3.897 99.621 -5.204
201506 -2.506 100.684 -3.311
201509 -2.870 100.392 -3.803
201512 4.448 99.792 5.929
201603 -2.451 100.470 -3.245
201606 -1.826 101.688 -2.389
201609 -1.780 101.861 -2.325
201612 1.096 101.863 1.431
201703 -1.948 102.862 -2.519
201706 -0.979 103.349 -1.260
201709 3.109 104.136 3.972
201712 -0.487 104.011 -0.623
201803 -0.374 105.290 -0.473
201806 -0.343 106.317 -0.429
201809 -0.280 106.507 -0.350
201812 -0.283 105.998 -0.355
201903 0.271 107.251 0.336
201906 -0.922 108.070 -1.135
201909 -0.885 108.329 -1.087
201912 -0.420 108.420 -0.515
202003 -0.211 108.902 -0.258
202006 -0.235 108.767 -0.287
202009 -0.188 109.815 -0.228
202012 1.009 109.897 1.221
202103 -1.077 111.754 -1.282
202106 -0.292 114.631 -0.339
202109 -0.757 115.734 -0.870
202112 1.461 117.630 1.652
202203 -0.081 121.301 -0.089
202206 -0.358 125.017 -0.381
202209 -0.323 125.227 -0.343
202212 -0.321 125.222 -0.341
202303 -0.401 127.348 -0.419
202306 -0.580 128.729 -0.599
202309 -0.171 129.860 -0.175
202312 -0.314 129.419 -0.323
202403 -0.394 131.776 -0.398
202406 0.146 132.554 0.147
202409 -0.664 133.029 -0.664

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


XOMA Royalty  (STU:X0M1) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


XOMA Royalty Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


XOMA Royalty Business Description

Industry
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

XOMA Royalty Headlines

No Headlines